Head-To-Head Survey: Aclarion (NASDAQ:ACON) versus Firefly Neuroscience (NASDAQ:AIFF)

Aclarion (NASDAQ:ACON) and Firefly Neuroscience (NASDAQ:AIFF) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Aclarion and Firefly Neuroscience, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1	0	1	0	2.00
Firefly Neuroscience	1	0	0	0	1.00

Aclarion presently has a consensus price target of $7.50, indicating a potential upside of 188.46%. Given Aclarion’s stronger consensus rating and higher probable upside, equities analysts plainly believe Aclarion is more favorable than Firefly Neuroscience.

Profitability

This table compares Aclarion and Firefly Neuroscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,948.81%	-59.34%	-56.12%
Firefly Neuroscience	-506.23%	-90.17%	-72.05%

Risk and Volatility

Aclarion has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Firefly Neuroscience has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.

Insider and Institutional Ownership

7.5% of Aclarion shares are owned by institutional investors. Comparatively, 5.0% of Firefly Neuroscience shares are owned by institutional investors. 0.0% of Aclarion shares are owned by company insiders. Comparatively, 6.9% of Firefly Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Aclarion and Firefly Neuroscience”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$83,769.00	89.45	-$7.23 million	($7.40)	-0.35
Firefly Neuroscience	$1.80 million	9.33	-$19.88 million	($0.59)	-1.81

Aclarion has higher earnings, but lower revenue than Firefly Neuroscience. Firefly Neuroscience is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Summary

Aclarion beats Firefly Neuroscience on 10 of the 14 factors compared between the two stocks.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

About Firefly Neuroscience

Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.